Krebs Biochemicals & Industries
60.13
-0.15(-0.25%)
Market Cap₹129.64 Cr
PE Ratio-7.83
IndustryHealthcare
Company Performance:
1D-0.25%
1M-7.72%
6M-13.03%
1Y-31.51%
5Y-49.26%
View Company Insightsright
More news about Krebs Biochemicals & Industries
07Apr 26
Krebs Biochemicals & Industries Limited Files SEBI Compliance Certificate for Q4FY26
Krebs Biochemicals & Industries Limited has submitted its SEBI Regulation 74(5) compliance certificate for Q4FY26 through registrar KFIN Technologies Limited. The filing, made on April 7, 2026, covers the quarter ended March 31, 2026, and confirms compliance with depositories regulations. Certificates were provided to both NSDL and CDSL, verifying that securities dematerialization and rematerialization details were furnished to all relevant stock exchanges.
 no imag found
09Feb 26
Krebs Biochemicals Reports Q3FY26 Net Loss of ₹312.65 Lacs Amid Operational Challenges
Krebs Biochemicals & Industries announced Q3FY26 results showing net loss of ₹312.65 lacs, an improvement from ₹773.89 lacs loss in Q3FY24. Revenue declined 36.55% YoY to ₹727.42 lacs due to continued closure of Vizag manufacturing unit under pollution board orders. The company's financial position remains challenging with negative equity of ₹16,083.25 lacs.
 no imag found
04Nov 25
Krebs Biochemicals Reports Rs 1,146.71 Lakh Loss for H1 2025, Revenue at Rs 1,977.70 Lakh
Krebs Biochemicals & Industries Limited announced unaudited financial results for H1 2025, showing a reduced loss before tax of Rs 1,146.71 lakh compared to Rs 2,093.20 lakh in the previous year. Revenue from operations was Rs 1,977.70 lakh. The company's cash position weakened with cash and cash equivalents at Rs 12.71 lakh. The Vizag manufacturing unit remains closed due to a pollution control board order. The company operates in a single business segment with no subsidiaries or joint ventures.
 no imag found
08Aug 25
Krebs Biochemicals Reports Rs 532.43 Crore Loss in Q1, Appoints New MD & CEO
Krebs Biochemicals & Industries reported a net loss of Rs 532.43 crore for Q1, with total income from operations at Rs 549.26 crore. The company appointed Mr. Manish Kumar Jain as the new Managing Director and CEO, replacing Mr. Jitendra Shah who resigned. The Board addressed a fine for non-compliance with SEBI regulations, stating it has been rectified with the appointment of new Independent Directors.
 no imag found
07Aug 25
Krebs Biochemicals Appoints New MD & CEO, Announces Q1 Results
Krebs Biochemicals & Industries Ltd has appointed Manish Kumar Jain as the new Managing Director and CEO for a five-year term, effective August 7, replacing Jitendra Shah who resigned. The company has also restructured its Audit Committee and Stakeholder Relationship Committee, including Jain in both. The board approved Q1 financial results ending June 30, which were subject to limited review by auditors. These changes comply with SEBI regulations.
 no imag found
07Aug 25
Krebs Biochemicals Announces Q1 Results and Leadership Transition
Krebs Biochemicals & Industries has announced significant changes in its leadership structure alongside its Q1 2025 results. Manish Kumar Jain, a Chartered Accountant with 25 years of experience, has been appointed as the new Managing Director & CEO effective August 7, 2025, replacing Jitendra Shah. The company has also restructured its board committees, including the Audit Committee and Stakeholder Relationship Committee. The unaudited Q1 financial results ending June 30, 2025, were approved by the Board, though specific figures were not disclosed.
 no imag found
25Jul 25
Krebs Biochemicals & Industries' MD & CEO Jitendra Shah Steps Down
Jitendra Shah, Managing Director, CEO, and Director of Krebs Biochemicals & Industries Limited, has announced his resignation effective August 7, 2025, citing personal reasons. The resignation letter was submitted on July 25, 2025. The company has informed BSE Limited and the National Stock Exchange of India Ltd about this development. No successor has been announced yet, with the board expected to address the transition in the upcoming meeting on August 7, 2025.
 no imag found
1 Year Returns:-31.51%
Industry Peers
Sun Pharmaceutical
1,862.50
(-0.66%)
Divis Laboratories
6,579.00
(+0.33%)
Torrent Pharmaceuticals
4,620.10
(-0.81%)
Cipla
1,465.40
(+0.78%)
Dr Reddys Laboratories
1,357.10
(-1.35%)
Zydus Life Science
1,112.60
(-0.78%)
Lupin
2,419.00
(+0.40%)
Mankind Pharma
2,545.60
(+2.40%)
Aurobindo Pharma
1,578.70
(+2.02%)
Laurus Labs
1,517.40
(+1.14%)